Research programme: transdermal hydrogel patch therapeutics - Alliqua Biomedical

Drug Profile

Research programme: transdermal hydrogel patch therapeutics - Alliqua Biomedical

Alternative Names: Alliqua Hydrogel technology; Lidocaine hydrogel patch; Transdermal pain patch - Alliqua Biomedical

Latest Information Update: 22 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alliqua
  • Class Acetanilides; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 20 Apr 2017 Discontinued - Preclinical for Postherpetic neuralgia in USA (Transdermal)
  • 24 Oct 2013 Final pharmacokinetics and adverse events data from a preclinical trial in Postherpetic neuralgia released by Alliqua
  • 23 Jul 2013 Research programme: Transdermal hydrogel patch therapeutics - Alliqua is available for licensing as of 26 Jul 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top